These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 28720132

  • 21. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH, Rabe KF, Welte T.
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D.
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [Abstract] [Full Text] [Related]

  • 23. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 24. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 25. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
    Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.
    Int J Chron Obstruct Pulmon Dis; 2019 May; 14():531-546. PubMed ID: 30880943
    [Abstract] [Full Text] [Related]

  • 26. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N, Kaneko T.
    Int J Chron Obstruct Pulmon Dis; 2015 May; 10():813-22. PubMed ID: 25960646
    [Abstract] [Full Text] [Related]

  • 27. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.
    Respir Med; 2014 Dec 06; 108(12):1786-93. PubMed ID: 25307414
    [Abstract] [Full Text] [Related]

  • 29. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.
    Lancet; 2018 Mar 17; 391(10125):1076-1084. PubMed ID: 29429593
    [Abstract] [Full Text] [Related]

  • 30. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A, Babu KS, Morjaria JB.
    Int J Chron Obstruct Pulmon Dis; 2015 Mar 17; 10():111-23. PubMed ID: 25609944
    [Abstract] [Full Text] [Related]

  • 31. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.
    Int J Chron Obstruct Pulmon Dis; 2018 Mar 17; 13():3923-3936. PubMed ID: 30584293
    [Abstract] [Full Text] [Related]

  • 32. Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
    O'Doherty B, Dorman J, McGrath K, Kelly K, Molony D, Lacey S, Whelan S, Schmid S, Sullivan S.
    Ir J Med Sci; 2019 Nov 17; 188(4):1251-1259. PubMed ID: 30924006
    [Abstract] [Full Text] [Related]

  • 33. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov 17; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S, Sechaud R, Su Z, Tillmann HC, Hara H, Tan X, Hou J, Woessner R, Zhao R.
    Int J Clin Pharmacol Ther; 2017 Feb 17; 55(2):147-155. PubMed ID: 27841152
    [Abstract] [Full Text] [Related]

  • 35. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
    Ther Adv Respir Dis; 2015 Apr 17; 9(2):49-55. PubMed ID: 25691493
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
    Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, Wang Q, Kho P, Firth R, D'Andrea P.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr 17; 10():57-68. PubMed ID: 25609940
    [Abstract] [Full Text] [Related]

  • 37. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 17; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 17; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 39. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A, Zanardi E, Poletti V, Cazzola M.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 17; 10():1383-92. PubMed ID: 26229457
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 17; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.